Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials-Reference-Cited by-同舟云学术

Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials

Published:2017-09-14 Issue:4 Volume:14 Page:934-944
ISSN:1933-7213
Container-title:Neurotherapeutics
language:en
Short-container-title:Neurotherapeutics

Author:

Nowinski Cindy J.^ORCID,Miller Deborah M.,Cella David

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Neurology (clinical),Pharmacology

Link

http://link.springer.com/article/10.1007/s13311-017-0571-6/fulltext.html

Reference132 articles.

1. US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071975.pdf . Accessed 15 June 2017.

2. Edelman EJ, Gordon K, Justice AC. Patient and provider-reported symptoms in the post-cart era. AIDS Behav 2011;15:853-861.

3. Janse AJ, Gemke R, Uiterwaal C, et al. Quality of life: patients and doctors don't always agree: a meta-analysis. J Clin Epidemiol 2004;57:653-661.

4. Kremenchutzky M, Walt L. Perceptions of health status in multiple sclerosis patients and their doctors. Can J Neurol Sci 2013;40:210-218.

5. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: Cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ 1997;314:1580.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The patient-reported outcomes for the new brand-generic teriflunomide in relapsing-remitting multiple sclerosis;Clinical Neurology and Neurosurgery;2024-11

2. Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis;Journal of Neurology;2024-04-16

3. Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-04

4. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis;Advances in Therapy;2023-09-30

5. Within-person fluctuations over three years in depression, anxiety, fatigue, and health-related quality of life in multiple sclerosis;Multiple Sclerosis Journal;2023-08-03